A Patient with Beta-Propeller Protein-Associated Neurodegeneration: Treatment with Iron Chelation Therapy

We present a case of beta-propeller protein-associated neurodegeneration, a form of neurodegeneration with brain iron accumulation. The patient harbored a novel mutation in the WDR45 gene. A detailed video and description of her clinical condition are provided. Her movement disorder phenomenology was characterized primarily by limb stereotypies and gait dyspraxia. The patient’s disability was advanced by the time iron-chelating therapy with deferiprone was initiated, and no clinical response in terms of cognitive function, behavior, speech, or movements were observed after one year of treatment.

[1]  R. Pagon,et al.  Beta-Propeller Protein-Associated Neurodegeneration -- GeneReviews® , 2020 .

[2]  J. Jankovic,et al.  Treatable inherited rare movement disorders , 2018, Movement disorders : official journal of the Movement Disorder Society.

[3]  E. Granieri,et al.  Patient Affected by Beta-Propeller Protein-Associated Neurodegeneration: A Therapeutic Attempt with Iron Chelation Therapy , 2017, Front. Neurol..

[4]  S. Danda,et al.  Beta Propellar Protein-Associated Neurodegeneration: A Rare Cause of Infantile Autistic Regression and Intracranial Calcification. , 2016, Neuropediatrics.

[5]  J. Holton,et al.  Neuropathology of Beta-propeller protein associated neurodegeneration (BPAN): a new tauopathy , 2015, Acta Neuropathologica Communications.

[6]  G. Oyama,et al.  High frequency of beta-propeller protein-associated neurodegeneration (BPAN) among patients with intellectual disability and young-onset parkinsonism , 2015, Neurobiology of Aging.

[7]  G. Cossu,et al.  Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up. , 2014, Parkinsonism & related disorders.

[8]  T. Wieland,et al.  Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. , 2012, American journal of human genetics.

[9]  Alessandra Solari,et al.  Iron‐related MRI images in patients with pantothenate kinase–associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial , 2011, Movement disorders : official journal of the Movement Disorder Society.

[10]  Nathalie Boddaert,et al.  Selective iron chelation in Friedreich ataxia: biologic and clinical implications. , 2007, Blood.